Mirum files updated risk factor disclosure; no financial or operational news

Mirum Pharmaceuticals, Inc.

Update includes risks related to sole-source contract manufacturers for commercial supplies.
Lists risk of needing additional financing for commercialization and product development.
Notes potential delays in patient enrollment and clinical trial completion.
References the Asset Purchase and risk of not realizing its anticipated benefits.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.